Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/18/2026 | $83.00 | Hold | Truist |
| 1/22/2026 | $83.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 1/7/2026 | Peer Perform | Wolfe Research | |
| 12/17/2025 | $95.00 | Overweight | Stephens |
| 12/10/2025 | $103.00 | Buy | Deutsche Bank |
| 11/3/2025 | $109.00 | Buy | Craig Hallum |
| 10/21/2025 | $105.00 | Outperform | Mizuho |
| 9/25/2025 | $60.00 | Outperform | RBC Capital Mkts |
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients maintained EASI-75- 86% and 78% patients maintained vIGA 0/1Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart Well tolerated across both dosing regimens, with safety profile generally in line with other agents in class APEX Part B 16-week induction expected to readout 2Q 2026, supporting expected initiation of Phase 3 zumilokibart trials in moderate-to-severe atopic dermatitis starting in 2H 2026 Dat
SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast DetailsApogee Therapeutics' live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via this l
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway:- APEX Phase 2 Part A 52-week data expected this month- APEX Phase 2 Part B 16-week data expected in Q2 2026- Phase 3 trial initiation in AD anticipated in 2H 2026- Successful expansion of zumilokibart beyond AD demonstrated in asthma Phase 1b trial; details on asthma and eosinophilic esophagitis (EoE) trials expected later this year Phase 1b head-to-head trial of APG279 (zumilokibart + APG990) vs. DUPIXENT underway, with interim AD data anticipated in 2H 2026 Strong total cash position of $902.9 million with runway into 2H 2028 supports advancement toward potential laun
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
SCHEDULE 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
S-8 - Apogee Therapeutics, Inc. (0001974640) (Filer)
Truist initiated coverage of Apogee Therapeutics with a rating of Hold and set a new price target of $83.00
RBC Capital Mkts downgraded Apogee Therapeutics from Outperform to Sector Perform and set a new price target of $83.00
Wolfe Research initiated coverage of Apogee Therapeutics with a rating of Peer Perform
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients maintained EASI-75- 86% and 78% patients maintained vIGA 0/1Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart Well tolerated across both dosing regimens, with safety profile generally in line with other agents in class APEX Part B 16-week induction expected to readout 2Q 2026, supporting expected initiation of Phase 3 zumilokibart trials in moderate-to-severe atopic dermatitis starting in 2H 2026 Dat
SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast DetailsApogee Therapeutics' live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via this l
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up - Results reinforce continued development in asthma testing every 3- or 6-month dosing Successful expansion of zumilokibart beyond dermatology confirms its pipeline-in-a-product potential across I&I indications Zumilokibart in atopic dermatitis (AD) advancing in Phase 2 APEX trials with goal of Phase 3 initiation by end of 2026:- Part A maintenance (52-week) data readout expected in Q1 2026 with potential to establish best-in-class e
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,